Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes.
Mikkel Bring ChristensenAsger B LundNiklas R JørgensenJens Juul HolstTina VilsbøllFilip K Krag KnopPublished in: Journal of the Endocrine Society (2020)
Short-term GIP infusions reduce the bone resorption marker CTX by one-third in patients with type 2 diabetes independent of glycemic levels.